Delayed HIV diagnosis common in Sweden, 2003-2010

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 12, 2014, Pages 862-867

  Widgren, Katarina ^a,b   Skar, Helena ^b,c,d,e   Berglund, Torsten ^a   Kling, Anna Maria ^a   Tegnell, Anders ^a   Albert, Jan ^b,d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Delayed diagnosis; HIV; Immunoassay; Risk factors; Trends

Indexed keywords

ADULT; AGE; AGED; ALGORITHM; ARTICLE; BED ASSAY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; GENDER; GROUPS BY AGE; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; RECENT INFECTION TESTING ALGORITHM; SWEDEN; VIRUS TRANSMISSION; YOUNG ADULT; DRUG USE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE HOMOSEXUALITY; RISK FACTOR; SEX DIFFERENCE; SEXUAL BEHAVIOR; STATISTICAL MODEL;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; DELAYED DIAGNOSIS; DRUG USERS; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SEXUAL BEHAVIOR; SWEDEN; YOUNG ADULT;

EID: 84911364185     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.953575     Document Type: Article

References (27)

1. HIV testing: increasing uptake and effectiveness in the European Union. Stockholm: European Centre for Disease Prevention and Control (ECDC); 2010. Available from: http://www.ecdc.europa.eu/en/publications/publications/101129-Ter-hiv-Testing-evidence.pdf
2. Adler A, Mounier-Jack S, Coker R J. Late diagnosis of HIV in Europe: defi nitional and public health challenges. AIDS Care 2009; 21: 284-93.
3. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus defi nition. HIV Med 2011; 12: 61-4.
4. Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, et al. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 2010; 24: 2697-704.
5. Antiretroviral treatment of HIV infection 2013, updated recommendations. [Antiretroviral behandling av HIV-infektion 2013, uppdaterad rekommendation.] Swedish reference group for antiretroviral therapy (RAV); 2013. Available from: http://www.folkhalsomyndigheten.se/documents/projektwebbar/rav/rekommendationer/rav-behandling-Antiviral-hivinfektion-2013-uppdaterad-version.pdf
6. Bärnighausen T, McWalter T A, Rosner Z, Newell ML, Welte A. HIV incidence estimation using the BED capture enzyme immunoassay: systematic review and sensitivity analysis. Epidemiology 2010; 21: 685-97.
7. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, et al. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 2011; 27: 265-73.
8. Busch M P, Pilcher C D, Mastro TD, Kaldor J, Vercauteren G, Rodriguez W, et al. Beyond detuning: 10years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010; 24: 2763-71.
9. Guy R, Gold J, Calleja J M, Kim AA, Parekh B, Busch M, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 2009; 9: 747-59.
10. Methods for estimating HIV incidence. U NAIDS; 2010. Available from: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/basedocument/2010/epi-Alert-1stqtr2010-en.pdf
11. Monitoring recently acquired HIV infections in the European context. Stockholm: European Centre for Disease Prevention and Control (ECDC); 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/monitoring-recently-Acquired-HIV-infections-european-context.pdf
12. HIV in the United Kingdom: 2 013 report. H ealth Protection Agency; 2013. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317140300680
13. National Strategy to Combat HIV/AIDS and Certain Other Communicable Diseases. Government Bill 2005/06:60. [Nationell strategi mot hiv/aids och vissa andra smittsamma sjukdomar. Regeringens proposition 2005/06:60.] Available from: http://www.regeringen.se/sb/d/108/a/55679
14. Karlsson A, B j ör kman P, Bratt G, Ekvall H, Gissl é n M, S ö nnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003- 2010. PloS One 2012 ;7: e33484.
15. SPREADprogramme. T ransmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
16. Skar H, Albert J, Leitner T. Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PloS One 2013; 8: e60906.
17. d'Arminio Monforte A, Cozzi-Lepri A, Girardi E, Castagna A, Mussini C, Di Giambenedetto S, et al. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther 2011; 16: 1103-12.
18. Chadborn TR, Delpech V C, Sabin C A, Sinka K, Evans B G. The late diagnosis and consequent short-Term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006; 20: 2371-9.
19. Chadborn T R, Baster K, Delpech V C, Sabin C A, Sinka K, Rice BD, et al. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005; 19: 513-20.
20. Marks G, Crepaz N, Senterfi tt J W, Janssen R S. Metaanalysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defi c Syndr 2005; 39: 446-53.
21. Bontell I, Haggblom A, Bratt G, Albert J, Sonnerborg A. Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011. PloS One 2013; 8: e59337.
22. Global AIDS Response Progress Report 2012, Sweden. Swedish Institute for Communicable Disease Control; 2012. Available from: http://www.folkhalsomyndigheten. se/pagefiles/12846/global-Aids-response-progress-report. Pdf Cohen
23. MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
24. Skar H, Axelsson M, Berggren I, Thalme A, Gyllensten K, Liitsola K, et al. Dynamics of two separate but linked HIV-1 CRF01-AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. J Virol 2011; 85: 510-18.
25. Le Vu S, Le Strat Y, Barin F, Pillonel J, Cazein F, Bousquet V, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010; 10: 682-7.
26. Bä t zing-Feigenbaum J, Loschen S, Gohlke-Micknis S, Zimmermann R, Herrmann A, Kamga Wambo O, et al. Country-wide HIV incidence study complementing HIV surveillance in Germany. Euro Surveill 2008; 13(36) pii: 18971.
27. Brä n nstr öm J, Svedhem V, Yilmaz A, Blaxhult A, Wendahl S, S ö nnerborg A. Ahigh occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden. Journal of the International AIDS Society 2010; 13(Suppl 4): 169.